Menu Actualizing the Untapped Potential of the Innate Immune System Read more News Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas November 22, 2021 Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing November 12, 2021 more news Events 11 Dec ASH ANNUAL MEETING & EXPOSITION December 11 - 14, 2021 (Georgia World Congress Center - Atlanta, GA) 29 Mar Innate Killer Summit March 29 - April 1, 2022 (San Diego, CA) more events Our Mission We are a team of innate immunity experts unrelenting in our efforts to change the meaning of cancer With our differentiated approach to arming the body’s innate immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies. read more Our Approach Redirecting innate cells to recognize and kill tumor cells We are actualizing the next advancement in immuno-oncology (I-O) through our proprietary ROCK® platform, which stands for Redirected Optimized Cell Killing. Our new approach to build ROCK® based innate cell engagers aims to treat a broad range of hematologic and solid tumors by countering tumor immune evasion through activating a patient’s own innate immune system. read more about our approach Our Pipeline Targeting hematological and solid tumors with differentiated and versatile innate cell engagers Our ROCK® platform-designed tetravalent bispecific innate cell engagers are being studied in a number of clinical and preclinical programs. These innate cell engagers are the first to demonstrate a favorable safety profile and promising signs of therapeutic efficacy. learn more about our pipeline Innate Cell Engagers AFM13 Disease Target CD30 Peripheral T cell lymphoma (AFM13-202) Phase 2 Registration Directed, Enrolling Transformed mycosis fungoides (AFM13-202) Phase 2 POC CD30-positive T cell lymphoma (AFM13-102) Phase 2 POC, Completed HL (post BV and post anti-PD-1) (AFM13-201) Phase 2 POC, Enrollment Completed AFM13 + adoptive NK cells Disease Target CD30 CD30-positive lymphoma (AFM13-104) Phase 1 Safety & POC, Enrolling AFM13 + anti-PD-1 Disease Target CD30 Hodgkin lymphoma (post BV) (AFM13-103) Phase 1 POC, Study Completed AFM24 Disease Target EGFR Solid tumors (AFM24-101) Phase 1 Safety & POC, Enrolling AFM24 + adoptive NK cells Disease Target EGFR Multiple solid tumors (AFM24-103) Phase 1 AFM24 + anti-PD-L1 Disease Target EGFR Multiple solid tumors (AFM24-102) IND not required AFM28 Disease Target CD123 Acute Myeloid Leukemia Pre-IND Genentech Disease Target Undisclosed Multiple Programs Pre-IND ICE® + NK cell combination: co-vialed, cryopreserved, off-the-shelf Disease Target Undisclosed Undisclosed Pre-IND Affimed programs Partnered programs Affimed GmbH Technologiepark Im Neuenheimer Feld 582 69120 Heidelberg, Germany Phone: +49 (0)6221-6743-60 Fax: +49 (0)6221 6743-649 info@affimed.com About Affimed Management Team Supervisory Board Partners ROCK® Platform Pipeline Innate Cell Engagers Publications & Posters News & Events Past Events Webcasts and Corporate Presentation Investors Webcasts and Corporate Presentation Analyst Coverage Share Information SEC & Financial Reports Corporate Governance Press Release Distribution Careers Culture © 2021 Affimed GmbH Data Protection Imprint Contact